Main Article Content


L.R. Syzdykova

National center for biotechnology, 13/5 Korgalzhyn Road, Astana, 010000, Kazakhstan

V.V. Keyer

National center for biotechnology, 13/5 Korgalzhyn Road, Astana, 010000, Kazakhstan

R.Y. Arsienko

National center for biotechnology, 13/5 Korgalzhyn Road, Astana, 010000, Kazakhstan

B.K. Inirbay

National center for biotechnology, 13/5 Korgalzhyn Road, Astana, 010000, Kazakhstan

A.V. Shustov

National center for biotechnology, 13/5 Korgalzhyn Road, Astana, 010000, Kazakhstan


Therapy of hematological tumors with chimeric antigen receptor-expressing T-cells (CAR-T) is a recent technology which holds promise to become the most significant achievement in oncohematology over the past 20 years. One aspect of the clinically applied CAR-T technology is that the process of production of CAR+ cells requires viral vectors which are used to deliver the CAR gene in T lymphocytes. At present the production of CAR-T therapy depends on the availability of packaged lentiviral or retroviral vectors. There is a worldwide deficiency in a production capacity to produce CAR vectors, and clinical-use vectors are not sold as off-the-shelf products.

At the National center for biotechnology the CAR receptor was assembled and this CAR targets the CD19 antigen which is a marker of tumor cells of the B-cell origin, lentiviral vectors were constructed. Studies on the production of packaged vectors were conducted at which three types of transfection reagents were compared for efficiency, in terms of the produced functional titers. A method was developed to measure functional titers using flow cytometry. High titers of the packaged vectors were obtained.

As the CAR-T is effective for treatment of patients after failure of traditional therapy, with relapse or refractory disease, all works on transfer of the CAR-T technology to Kazakhstan are of life importance to the patients with blood cancers in the country. The results underscore a necessity to organize a full production process to produce CAR vectors for clinical use and therapeutic cells for the CAR-T therapy at the NCB.


viral vectors, CAR-T therapy, transfection, lentiviruses, polyethylenimine, hematological tumors

Article Details


Quinonez R., Sutton R.E. Lentiviral Vectors for Gene Delivery into Cells // DNA and Cell Biology. – 2004. – Vol. 21, № 12. – P. 937-951. Crossref

Labanieh L., Majzner R.G., Mackall C.L. Programming CAR-T cells to kill cancer // Nature Biomedical Engineering. – 2018. – Vol. 2. – P. 377-391. Crossref

Perica K., Varela J.C., Oelke M., Schneck J. Adoptive T Cell Immunotherapy For Cancer // Cancer Immunotherapy. – 2015. – Vol. 6, № 1. – P. e0004. Crossref

Rafic S., Hackett C.S., Brentjens R.J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy // Nature Reviews Clinical Oncology. – 2020. – Vol. 17. – P. 147-167. Crossref

Maude S.L., Laetsch T.W., Buechner J., Rives S., Boyer M., Bittencourt H., Bader P., Verneris M.R., Stefanski H.E., Myers G.D., Qayed M., De Moerloose B., Hiramatsu H., Schlis K., Davis K.L., Martin P.L., Nemecek E.R. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia // N. Engl. J. Med. - 2018. - Vol. 378, No. 5. - P. 439-448. Crossref

Shah B.D., Ghobadi A., Oluwole O.O., Logan A.C., Boissel N., Cassaday R.D., Leguay T., Bishop M.R., Topp M.S., Tzachanis D., Arellano M.L., Lin Y., Baer, M.R., Schiller G.J., Park J.H., Subklewe M., Abedi M. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study // Lancet. - 2021. - Vol. 398. - P.491-502. Crossref

Abramson J.S., Palomba M.L., Gordon L.I., Lunning M.A., Wang M., Arnason J., Mehta A., Purev E., Maloney D.G., Andreadis C., Sehgal A., Solomon S.R., Ghosh N., Albertson T.M., Garcia J., Kostic A., Mallaney M., Ogasawara K. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study // Lancet. - 2020. - Vol. 396. - P. 839-852. Crossref

Neelapu S.S., Locke F.L., Bartlett N.L., Lekakis L.J., Miklos D.B., Jacobson C.A., Braunschweig I., Oluwole O.O., Siddiqi T., Lin Y., Timmerman J.M., Stiff P.J., Friedberg J.W., Flinn I.W., Goy A., Hill B.T., Smith M.R. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma // N. Engl. J. Med. – 2017. – Vol. 377, - 2017. - Vol. 377, № 26. – P. 2531-2544. Crossref

Schuster S.J., Svoboda J., Chong E.A., Nasta S.D., Mato A.R., Anak Ö., Brogdon J.L., Pruteanu-Malinici I., Bhoj V., Landsburg D., Wasik M., Levine B.L., Lacey S.F., Melenhorst J.J., Porter D.L., June C.H. Chimeric antigen receptor T cells in refractory B-cell lymphomas // N. Engl. J. Med. – 2017. – Vol. 377, № 26. – P. 2545-2554. Crossref

Wang M., Munoz J., Goy A., Locke F.L., Jacobson C.A., Hill B.T., Timmerman J.M., Holmes H., Jaglowski S., Flinn I.W., McSweeney P.A., Miklos D.B., Pagel J.M., Kersten M.J., Milpied N. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma // N. Engl. J. Med. – 2020. – Vol. 382, № 14. – P. 1331-1342. Crossref

Stanton D. Commercial CAR-Ts: Ensuring lentivirus supply key for J&J and BMS // BioProcess International. – 2022. URL

Sadelain M., Brentjens R., Rivière I. The basic principles of chimeric antigen receptor design // Cancer Discov. – 2013. – Vol. 3, № 4. – P. 388-398. Crossref

Rodrigues A., Alves P. M., Coroadinha A. Production of retroviral and lentiviral gene therapy vectors: challenges in the manufacturing of lipid enveloped virus // Viral Gene Therapy. – 2011. - Crossref

Miller A.D. Retroviral vectors: from cancer viruses to therapeutic tools // Human Gene Tharapy. – 2014. – Vol. 25, № 12. – P. 989-994. Crossref

Irving M., Lanitis E., Migliorini D., Ivics Z., Guedan S. Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen receptor-T cells // Human Gene Therapy. – 2021. – Vol. 32, № 19. – P. 1044-1058. Crossref

Ding P., Kharytonchyk S., Kuo N., 5’-Cap sequestration is an essential determinant of HIV-1 genome packaging // PNAS. – 2021. – Vol. 118, № 37. – P. e2112475118. Crossref

Merten O-W., Hebben M., Boolenta C. Production of lentiviral vectors // Mol. Ther. Methods Clin Dev. – 2016. – Vol. 3. – P. 16017. Crossref

Allahverdi A., Eskandari F. Lentiviral vectors titration using real-time PCR // Archives of Advances in Biosciences. – 2015. – Vol. 6, № 1. – P. 80-84. Crossref

Tang Y., Garson K., Li L., Vanderhuden B.C. Optimization of lentiviral vector production using polyethylenimine mediated transfection // Oncology letters. - 2014. – Vol. 9, № 1. – P. 55-62. Crossref